Please assess the completion status of the following clinical trial:

Trial Title: A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* With ≥ 1 diagnosis for IPF (the International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] codes 516.3, 516.31, 515, or ICD-10-CM codes J84.112) in the EMR between October 1, 2013 to April 30, 2018~* With ≥ 1 prescription for nintedanib between October 1, 2014 and April 30, 2018 (the selection window)~* The date of the first prescription will be defined as the index date~* With ≥ 1 record in the EMR database during the 12 months prior to the index date (the pre-index period)~* With ≥ 1 diagnosis of IPF during the 12 months prior to the index date~* Age ≥ 40 on the index date~* IQVIA will explore also requiring ≥ 1 chest CT scan before first IPF diagnosis during the pre-index period~Exclusion Criteria:~* With ≥ 1 diagnosis of other known causes of interstitial lung disease (ILD) on the date of or after the first IPF diagnosis during the pre-index period~* Other known causes of ILD include conditions such as systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, Sjögren disease, and hypersensitivity pneumonitis (ICD-9-CM codes 135, 237.7, 272.7, 277.3, 277.8, 446.21, 446.4, 495, 500-505, 506.4, 508.1, 508.8, 516.0, 516.1, 516.32-516.37, 516.2, 516.8, 516.9, 517.0, 517.2, 517.8, 518.3, 555, 710.0, 710.0-710.4, 714.0, 714.81, 720, and 759.5, or ICD-10-CM equivalent codes)~* With ≥ 1 prescription for nintedanib prior to the index date~* With ≥ 1 prescription for pirfenidone prior to or on the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with Idiopathic Pulmonary Fibrosis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).